文献速递头痛与眩晕

多潘立酮治疗双氢麦角胺输注相关恶心与头痛的安全性

Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.
PubMed 文献 · Neurology · 2016-11-11

该回顾性审计纳入了90例因静脉双氢麦角胺(DHE)输注住院的103次连续入院,其中85次使用多潘立酮止吐,剂量最高80 mg/d。结果显示多潘立酮耐受良好,仅1例出现静坐不能,21例重复心电图显示校正QT间期(QTc)用药前后无显著差异(P=0.15),且无患者因难治性恶心限制DHE剂量。

要点

  • 多潘立酮在DHE输注相关恶心治疗中耐受良好,严重副作用罕见。
  • 重复心电图显示多潘立酮未显著延长QTc间期。
  • 多潘立酮联合其他止吐药可有效控制恶心,避免限制DHE剂量。

核心结论

  • 回顾性审计表明多潘立酮用于住院DHE输注相关恶心和头痛的治疗是安全的,但需更大前瞻性试验确认疗效。

研究设计与样本

  • 回顾性审计,纳入90例患者的103次连续入院,多数为慢性偏头痛(有先兆53次,无先兆46次)。

主要发现

  • 85次入院使用多潘立酮,剂量最高80 mg/d,仅1例出现静坐不能。
  • 21例患者用药后重复心电图,QTc用药前后无显著差异(中位数435.0 ms vs 427.0 ms,P=0.15)。
  • 多潘立酮联合其他止吐药有效控制恶心,无患者因难治性恶心限制DHE剂量。

关键数值与推荐

  • 多潘立酮剂量最高80 mg/d;QTc中位数入院时435.0 ms(IQR 410.5-453.0),用药后427.0 ms(IQR 399.0-452.5),P=0.15。

临床怎么用

  • 对于接受DHE输注的头痛患者,多潘立酮可用于治疗恶心,但需关注已知安全风险如心律失常。

局限性

  • 回顾性审计设计,样本量有限,仅21例获得重复心电图,需更大前瞻性试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the safety of domperidone in the treatment of nausea associated with dihydroergotamine (DHE) infusion and headache. METHODS: We audited our use of domperidone for the inpatient management of nausea, focusing on known safety concerns, particularly potential cardiac arrhythmias. RESULTS: We reviewed 103 consecutive admissions of 90 patients admitted for IV DHE by infusion. Most admissions were to treat chronic migraine with (n = 53) or without (n = 46) aura. Domperidone was administered in 85 of 103 encounters and was well-tolerated at doses up to 80 mg/d. A significant side effect, akathisia, was observed in one patient. Baseline ECG with corrected QT interval (QTc) was obtained on all patients. Repeat ECG after domperidone was obtained in 21 patients, whose baseline characteristics did not differ from the group as a whole. ECG was interpreted blindly by a cardiac electrophysiologist. QTc did not differ before and after domperidone administration (Wilcoxon signed-rank test, median [interquartile range] 435.0 [410.5-453.0] at admission and 427.0 [399.0-452.5] after domperidone; p = 0.15). In combination with other antiemetics, domperidone was effective in treating nausea such that no patients had refractory nausea severe enough to limit DHE dose. CONCLUSIONS: This retrospective audit demonstrates that domperidone is safe in the treatment of nausea associated with inpatient DHE infusion and headache. While larger prospective trials are necessary to confirm these results and assess efficacy, current evidence and clinical experience suggests that domperidone is safe and useful for nausea and headache management. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with headache undergoing DHE infusion, domperidone is safe and effective in the treatment of nausea.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Robbins NM, Ito H, Scheinman MM, et al. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology. 2016. PMID: 27837002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。